PDCD1 and melanoma: For example, lung cancer patients treated with either pembrolizumab or nivolumab, the median time to onset of anti‐PD‐1 and anti‐PD‐L1 therapy‐induced hepatotoxicity was 25 weeks (range: 4‐31 weeks), while it was 4 weeks (range: 0.1‐23 weeks) in the melanoma patients treated with nivolumab, and 19 weeks (range: 0.3‐93 weeks) in those treated with pembrolizumab.28